Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 5/20 | 0.53 |
| ▸ | CCR5 | P51681 | 16/20 | 0.48 |
| ▸ | CCR7 | P32248 | 1/20 | 0.44 |
| ▸ | CCR3 | P51677 | 1/20 | 0.43 |
| ▸ | CCR4 | P51679 | 1/20 | 0.43 |
| ▸ | CXCR5 | P32302 | 1/20 | 0.41 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6350708 | 0.97 | CCR2 (0.52) | CCR2CCR5CCR7CCR3CCR4 | |
| SCHEMBL6341719 | 0.95 | CCR2 (0.53) | CCR2CCR5CCR7CCR3CCR4 | |
| SCHEMBL6342683 | 0.94 | CCR2 (0.51) | CCR2CCR5CCR7CCR3CCR4 | |
| SCHEMBL6340444 | 0.94 | CCR2 (0.52) | CCR2CCR5CCR7CCR3CCR4 | |
| SCHEMBL6344879 | 0.92 | CCR2 (0.49) | CCR2CCR5CCR7CCR3CCR4 | |
| SCHEMBL6351882 | 0.92 | CCR2 (0.49) | CCR2CCR5CCR7CCR3CCR4 | |
| SCHEMBL3031959 | 0.91 | CCR2 (0.53) | CCR2CCR5CCR7CCR3CCR4 | |
| SCHEMBL6412038 | 0.91 | CCR2 (0.49) | CCR2CCR5CCR7CCR3CCR4 | |
| SCHEMBL6151154 | 0.91 | CCR2 (0.50) | CCR2CCR5CCR7CCR3CCR4 | |
| SCHEMBL3029085 | 0.90 | CCR2 (0.56) | CCR2CCR5CCR7CCR3CCR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050245537-A1 | Use of compounds having ccr antagonism | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | claimed |
| US-6936602-B1 | Benzazepine derivatives, process for the preparation of the same and uses thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-30 | — | — | US | claimed |
| US-20050154016-A1 | Preventives for hiv infection | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-14 | — | — | US | claimed |
| EP-1498138-A1 | PREVENTIVES FOR HIV INFECTION | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | claimed |
| EP-1498125-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | claimed |
| EP-1186604-A1 | BENZAZEPINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-03-13 | — | — | EP | claimed |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | TSUCHIMORI NOBORU | 2010-08-26 | — | — | US | disclosed |
| US-20050245537-A1 | Use of compounds having ccr antagonism | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-11-03 | — | — | US | disclosed |
| US-6936602-B1 | Benzazepine derivatives, process for the preparation of the same and uses thereof | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2005-08-30 | — | — | US | disclosed |
| US-20050154016-A1 | Preventives for hiv infection | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-07-14 | — | — | US | disclosed |
| EP-1498138-A1 | PREVENTIVES FOR HIV INFECTION | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | disclosed |
| EP-1498125-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | Takeda Pharmaceutical Company Limited (JP) | 2005-01-19 | — | — | EP | disclosed |
| EP-1186604-A1 | BENZAZEPINE DERIVATIVES, PROCESS FOR THE PREPARATION OF THE SAME AND USES THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2002-03-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050154016-A1 | Preventives for hiv infection | CCR5, CCR2, CCR1 | CCR2 2/4885CCR5 1/4885CCR7 17/4885 |
| US-20050245537-A1 | Use of compounds having ccr antagonism | CCR1, CCR3, CCR2 | CCR2 3/4885CCR5 9/4885CCR7 13/4885 |
| US-20100216871-A1 | USE OF COMPOUNDS HAVING CCR ANTAGONISM | CCR1, CCR3, CCR2 | CCR2 3/4885CCR5 9/4885CCR7 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.